Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Nov 30, 2022 9:40am
212 Views
Post# 35139346

RE:JonesTrading initiates Buy & sets $6 price target

RE:JonesTrading initiates Buy & sets $6 price targetI have had a quick look at the report and it seems well done. It  is 36 pages long. He gives no value to NASH yet (Cantor gave it significant value) and more value to TH-1902 and the SORT1+ platform (he has some royalty payments factored in as well as direct revenues from it starting in 2026).

Jones is a retail oriented broker.  So, for those of us who have been asking for something on this front, here is your first answer. It will be interesting to see how things proceed now that we have this element involved. It has the potential to be quite consequential for the share price as it will not take a lot of new demand for the stock to move it meaningfully higher. And retail investors face none of the constraints institutional investors do.

PWIB123 wrote: Never heard of JonesTrading or the analyst Justin Walsh, but I'll take any positive news we can get.  


<< Previous
Bullboard Posts
Next >>